BRIEF published on 11/14/2025 at 18:05, 20 days 11 hours ago Biosynex: Grant received for a rapid preeclampsia test Public Health Grant BIOSYNEX Preeclampsia Quick Test
BRIEF published on 10/22/2025 at 18:05, 1 month 13 days ago BIOSYNEX SA: 2025 Half-Year Results and Safeguard Procedure Financial Results Turnover Financial Strategy Backup Procedure Depreciation Of Assets
BRIEF published on 09/29/2025 at 18:05, 2 months 5 days ago BIOSYNEX initiates financial restructuring and will liquidate its subsidiary AVALUN Financial Restructuring BIOSYNEX AVALUN Backup Procedure Compulsory Liquidation
BRIEF published on 09/25/2025 at 18:05, 2 months 9 days ago BIOSYNEX begins safeguard proceedings, AVALUN ceases payment Debt BIOSYNEX AVALUN Backup Procedure Cessation Of Payment
BRIEF published on 07/29/2025 at 18:50, 4 months 6 days ago Biosynex Achieves Breakthrough Device Status for Its Syphilis Test FDA Syphilis Breakthrough Device Rapid Diagnosis Chembio
BRIEF published on 07/17/2025 at 18:05, 4 months 18 days ago BIOSYNEX announces a decline in revenue for the first half of 2025 Restructuring Product Launches Turnover BIOSYNEX First Half Of 2025
BRIEF published on 05/06/2025 at 15:15, 6 months 29 days ago BIOSYNEX: Number of Shares and Voting Rights as of February 28, 2025 Share Capital Voting Rights Euronext Growth BIOSYNEX Health Diagnosis
BRIEF published on 04/23/2025 at 18:05, 7 months 11 days ago BIOSYNEX SA: 2024 Results and 2025 Reorganization Plan Financial Structure BIOSYNEX SA 2024 Results Export Growth Reorganization 2025
BRIEF published on 03/04/2025 at 18:05, 9 months ago BIOSYNEX: Declaration of the number of shares and voting rights Share Capital Voting Rights Actions BIOSYNEX Health Diagnosis
BRIEF published on 02/12/2025 at 08:05, 9 months 20 days ago BIOSYNEX successfully completes its capital increase Capital Increase Subscription BIOSYNEX Dilution Of Shareholders Oversubscription Rate
Published on 12/05/2025 at 02:35, 2 hours 48 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 23 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 18 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 23 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 53 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 32 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 58 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 8 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 13 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 23 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 38 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 39 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 22 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
